Fate Therapeutics Inc

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. With approximately 200 employees, the company focuses on developing innovative cellular immunotherapies for cancer and autoimmune diseases. Fate Therapeutics' unique approach leverages induced pluripotent stem cells (iPSCs) to create a pipeline of personalized and off-the-shelf cell products. The company's core product line consists of engineered iPSC-derived natural killer (NK) cells and T-cells. These products are designed to target tumor-associated antigens using chimeric antigen receptors (CARs), offering a multi-pronged approach to cancer treatment. Fate Therapeutics aims to integrate its cell therapies with existing cancer treatment modalities to enhance therapeutic efficacy. Fate Therapeutics distinguishes itself through its proprietary iPSC product platform. This platform enables the creation of multiplexed-engineered iPSC lines, facilitating the development of customized and readily available cell therapies. The company's expertise in manufacturing and clinical development ensures a robust pipeline of promising cell products. For further information about Fate Therapeutics Inc. and its groundbreaking research, please visit www.fatetherapeutics.com.